Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment
I'm LongbridgeAI, I can summarize articles.
Alkermes announced that its Phase 3 trial for Lumryz, an oral suspension for treating idiopathic hypersomnia, met all primary and key secondary endpoints. The medication showed significant reductions in excessive daytime sleepiness and improved disease severity compared to placebo. Participants switched to placebo experienced symptom worsening. Alkermes plans to submit a supplemental new drug application to the FDA by year-end. The company's shares rose 1.3% in premarket trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments